Category: Featured Story

The anti-cancer compound Gilotrif (afatinib) was granted approval by the U.S. Food and Drug Administration in July 2013 for patients with late stage non-small cell lung cancer whose tumors express specific types of epidermal growth factor receptor (EGFR) gene mutations. Now, the maker of the drug reports data from two independent Phase III clinical trials …

Last week, mesothelioma nurse, Lisa Hyde-Barrett reported on “super-responders” –  patients who have exceptional results in clinical trials. Researchers are using genome sequencing on these patients in hopes of finding a common genetic mutation that may result in additional patients having the same positive responses to the novel treatments. But genetic testing is not limited …

The mesothelioma community closely watches for any study that results in a better quality of life or extended survival for mesothelioma patients. With no cure and limited survival, mesothelioma is challenging to treat and patients are faced with a grim prognosis. Now, researchers in Japan report that the chemotherapy drug Alimta, when used as maintenance …